Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.90 USD
-0.22 (-10.38%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.90 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CHRS 1.90 -0.22(-10.38%)
Will CHRS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CHRS
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Other News for CHRS
Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Petiq (PETQ)
Coherus Biosciences price target raised by $1 at H.C. Wainwright, here's why
Buy Rating Affirmed for Coherus Biosciences Amid Strong Udenyca Sales and Strategic Financial Management
Coherus BioSciences: Q1 Earnings Snapshot
Coherus BioSciences Reports First Quarter 2024 Financial ResultsĀ and Provides Business Update